|
1
|
Tsao H, Chin L, Garraway LA and Fisher DE:
Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akbani R, Akdemir KC, Aksoy BA, Albert M,
Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, et al:
Cancer Genome Atlas Network: Genomic classification of cutaneous
melanoma. Cell. 161:1681–1696. 2015. View Article : Google Scholar
|
|
3
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dhomen N and Marais R: BRAF signaling and
targeted therapies in melanoma. Hematol Oncol Clin North Am.
23:529–545. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fecher LA, Amaravadi RK and Flaherty KT:
The MAPK pathway in melanoma. Curr Opin Oncol. 20:183–189. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al BRIM-3 Study Group; Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et
al: Inhibition of mutated, activated BRAF in metastatic melanoma. N
Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eggermont AM, Spatz A and Robert C:
Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar
|
|
10
|
Palmieri G, Ombra M, Colombino M, Casula
M, Sini M, Manca A, Paliogiannis P, Ascierto PA and Cossu A:
Multiple molecular pathways in melanomagenesis: Characterization of
therapeutic targets. Front Oncol. 5:1832015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johannessen CM, Boehm JS, Kim SY, Thomas
SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP,
Barretina J, et al: COT drives resistance to RAF inhibition through
MAP kinase pathway reactivation. Nature. 468:968–972. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poulikakos PI, Persaud Y, Janakiraman M,
Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al:
RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature. 480:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whittaker SR, Theurillat JP, Van Allen E,
Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE and Garraway
LA: A genome-scale RNA interference screen implicates NF1 loss in
resistance to RAF inhibition. Cancer Discov. 3:350–362. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Villanueva J, Infante JR, Krepler C,
Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M,
Vultur A, et al: Concurrent MEK2 mutation and BRAF amplification
confer resistance to BRAF and MEK inhibitors in melanoma. Cell
Reports. 4:1090–1099. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wagle N, Van Allen EM, Treacy DJ,
Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM,
Sullivan RJ, Farlow DN, et al: MAP kinase pathway alterations in
BRAF-mutant melanoma patients with acquired resistance to combined
RAF/MEK inhibition. Cancer Discov. 4:61–68. 2014. View Article : Google Scholar :
|
|
17
|
Shi H, Hugo W, Kong X, Hong A, Koya RC,
Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al:
Acquired resistance and clonal evolution in melanoma during BRAF
inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar :
|
|
18
|
Ascierto PA, Schadendorf D, Berking C,
Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck
JT, St-Pierre A, et al: MEK162 for patients with advanced melanoma
harbouring NRAS or Val600 BRAF mutations: A non-randomised,
open-label phase 2 study. Lancet Oncol. 14:249–256. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim DW and Patel SP: Profile of
selumetinib and its potential in the treatment of melanoma. Onco
Targets Ther. 7:1631–1639. 2014.PubMed/NCBI
|
|
20
|
King JW and Nathan PD: Role of the MEK
inhibitor trametinib in the treatment of metastatic melanoma.
Future Oncol. 10:1559–1570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Long GV, Weber JS, Infante JR, Kim KB,
Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, et
al: Overall survival and durable responses in patients with BRAF
V600-mutant metastatic melanoma receiving dabrafenib combined with
trametinib. J Clin Oncol. 34:871–878. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ascierto PA, McArthur GA, Dréno B,
Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L,
Stroyakovskiy D, Thomas L, et al: Cobimetinib combined with
vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM):
Updated efficacy results from a randomised, double-blind, phase 3
trial. Lancet Oncol. 17:1248–1260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Allen EM, Wagle N, Sucker A, Treacy
DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker
S, Kryukov GV, et al Dermatologic Cooperative Oncology Group of
Germany (DeCOG); The genetic landscape of clinical resistance to
RAF inhibition in metastatic melanoma. Cancer Discov. 4:94–109.
2014. View Article : Google Scholar
|
|
24
|
Welsh SJ, Rizos H, Scolyer RA and Long GV:
Resistance to combination BRAF and MEK inhibition in metastatic
melanoma: Where to next. Eur J Cancer. 62:76–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hassa PO and Hottiger MO: The diverse
biological roles of mammalian PARPS, a small but powerful family of
poly-ADP-ribose polymerases. Front Biosci. 13:3046–3082. 2008.
View Article : Google Scholar
|
|
26
|
Rouleau M, Patel A, Hendzel MJ, Kaufmann
SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev
Cancer. 10:293–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schreiber V, Amé JC, Dollé P, Schultz I,
Rinaldi B, Fraulob V, Ménissier-de Murcia J and de Murcia G:
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient
base excision DNA repair in association with PARP-1 and XRCC1. J
Biol Chem. 277:23028–23036. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Memisoglu A and Samson L: Base excision
repair in yeast and mammals. Mutat Res. 451:39–51. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schiewer MJ and Knudsen KE:
Transcriptional roles of PARP1 in cancer. Mol Cancer Res.
12:1069–1080. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tentori L, Muzi A, Dorio AS, Bultrini S,
Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, Nocentini G, et
al: Stable depletion of poly (ADP-ribose) polymerase-1 reduces in
vivo melanoma growth and increases chemosensitivity. Eur J Cancer.
44:1302–1314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Donawho CK, Luo Y, Luo Y, Penning TD,
Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL,
Dillehay LE, et al: ABT-888, an orally active poly(ADP-ribose)
polymerase inhibitor that potentiates DNA-damaging agents in
preclinical tumor models. Clin Cancer Res. 13:2728–2737. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishikawa T, Matsumoto K, Tamura K,
Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C,
Yonemori K, et al: Phase 1 dose-escalation study of single-agent
veliparib in Japanese patients with advanced solid tumors. Cancer
Sci. 108:1834–1842. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Middleton MR, Friedlander P, Hamid O, Daud
A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM,
et al: Randomized phase II study evaluating veliparib (ABT-888)
with temozolomide in patients with metastatic melanoma. Ann Oncol.
26:2173–2179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Palma JP, Wang YC, Rodriguez LE,
Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko
L, et al: ABT-888 confers broad in vivo activity in combination
with temozolomide in diverse tumors. Clin Cancer Res. 15:7277–7290.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carta F, Demuro PP, Zanini C, Santona A,
Castiglia D, D'Atri S, Ascierto PA, Napolitano M, Cossu A, Tadolini
B, et al: Analysis of candidate genes through a proteomics-based
approach in primary cell lines from malignant melanomas and their
metastases. Melanoma Res. 15:235–244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chang CC, Pirozzi G, Wen SH, Chung IH,
Chiu BL, Errico S, Luongo M, Lombardi ML and Ferrone S: Multiple
structural and epigenetic defects in the human leukocyte antigen
class I antigen presentation pathway in a recurrent metastatic
melanoma following immunotherapy. J Biol Chem. 290:26562–26575.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carriero MV, Bifulco K, Ingangi V,
Costantini S, Botti G, Ragone C, Minopoli M, Motti ML, Rea D,
Scognamiglio G, et al: Retro-inverso urokinase receptor antagonists
for the treatment of metastatic sarcomas. Sci Rep. 7:13122017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ragone C, Minopoli M, Ingangi V, Botti G,
Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA, Ciliberto G,
Motti ML, et al: Targeting the cross-talk between Urokinase
receptor and Formyl peptide receptor type 1 to prevent invasion and
trans-endothelial migration of melanoma cells. J Exp Clin Cancer
Res. 36:1802017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ascierto PA, Kirkwood JM, Grob JJ, Simeone
E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM and
Mozzillo N: The role of BRAF V600 mutation in melanoma. J Transl
Med. 10:852012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rom S, Zuluaga-Ramirez V, Reichenbach NL,
Dykstra H, Gajghate S, Pacher P and Persidsky Y: PARP inhibition in
leukocytes diminishes inflammation via effects on
integrins/cytoskeleton and protects the blood-brain barrier. J
Neuroinflammation. 13:2542016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rodríguez MI, Peralta-Leal A, O'Valle F,
Rodriguez-Vargas JM, Gonzalez-Flores A, Majuelos-Melguizo J, López
L, Serrano S, de Herreros AG, Rodríguez-Manzaneque JC, et al:
PARP-1 regulates metastatic melanoma through modulation of
vimentin-induced malignant transformation. PLoS Genet.
9:e10035312013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ascierto PA, Atkins M, Bifulco C, Botti G,
Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, et
al: Future perspectives in melanoma research: meeting report from
the 'Melanoma Bridge': Napoli, December 3rd-6th 2014. J Transl Med.
13:3742015. View Article : Google Scholar
|
|
43
|
Leonardi GC, Falzone L, Salemi R, Zanghì
A, Spandidos DA, Mccubrey JA, Candido S and Libra M: Cutaneous
melanoma: From pathogenesis to therapy (Review). Int J Oncol.
52:1071–1080. 2018.PubMed/NCBI
|
|
44
|
Staibano S, Pepe S, Lo Muzio L, Somma P,
Mascolo M, Argenziano G, Scalvenzi M, Salvatore G, Fabbrocini G,
Molea G, et al: Poly(adenosine diphosphate-ribose) polymerase 1
expression in malignant melanomas from photoexposed areas of the
head and neck region. Hum Pathol. 36:724–731. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tentori L, Leonetti C, Scarsella M,
D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J,
et al: Systemic administration of GPI 15427, a novel
poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor
activity of temozolomide against intracranial melanoma, glioma,
lymphoma. Clin Cancer Res. 9:5370–5379. 2003.PubMed/NCBI
|
|
46
|
Lok BH, Gardner EE, Schneeberger VE, Ni A,
Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell
SN, et al: PARP inhibitor activity correlates with SLFN11
expression and demonstrates synergy with temozolomide in small cell
lung cancer. Clin Cancer Res. 23:523–535. 2017. View Article : Google Scholar :
|
|
47
|
Ohmoto A and Yachida S: Current status of
poly(ADP-ribose) polymerase inhibitors and future directions.
OncoTargets Ther. 10:5195–5208. 2017. View Article : Google Scholar
|
|
48
|
Wagner LM: Profile of veliparib and its
potential in the treatment of solid tumors. OncoTargets Ther.
8:1931–1939. 2015. View Article : Google Scholar
|
|
49
|
Sonnenblick A, de Azambuja E, Azim HA Jr
and Piccart M: An update on PARP inhibitors - moving to the
adjuvant setting. Nat Rev Clin Oncol. 12:27–41. 2015. View Article : Google Scholar
|
|
50
|
Barboro P, Ferrari N, Capaia M, Petretto
A, Salvi S, Boccardo S and Balbi C: Expression of nuclear matrix
proteins binding matrix attachment regions in prostate cancer.
PARP-1: New player in tumor progression. Int J Cancer.
137:1574–1586. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Inbar D, Cohen-Armon M and Neumann D:
Erythropoietin-driven signalling and cell migration mediated by
polyADP-ribosylation. Br J Cancer. 107:1317–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhu M, Li W, Dong X, Chen Y, Lu Y, Lin B,
Guo J and Li M: Benzyl-isothiocyanate induces apoptosis and
inhibits migration and invasion of hepatocellular carcinoma cells
in vitro. J Cancer. 8:240–248. 2017. View Article : Google Scholar :
|
|
53
|
Tentori L, Leonetti C, Scarsella M,
Vergati M, Xu W, Calvin D, Morgan L, Tang Z, Woznizk K, Alemu C, et
al: Brain distribution and efficacy as chemosensitizer of an oral
formulation of PARP-1 inhibitor GPI 15427 in experimental models of
CNS tumors. Int J Oncol. 26:415–422. 2005.PubMed/NCBI
|
